EXCLUSIVE LICENSE AND SUBLICENSE AGREEMENT by and between VISTAGEN THERAPEUTICS, INC. and APOLLO BIOLOGICS LP EXCLUSIVE LICENSE AND SUBLICENSE AGREEMENTLicense Agreement • May 1st, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement is effective as of December 9, 2016 (the “Effective Date”), by and between VistaGen Therapeutics, Inc., a California corporation located at 343 Allerton Avenue, South San Francisco, CA 94080 (“VistaGen”), and Apollo Biologics LP, a Delaware limited partnership located at c/o Versant Venture Management, LLC, One Sansome, Suite 3630, San Francisco, CA 94104 (“Apollo”). VistaGen and Apollo are each sometimes referred to herein as a “Party” or collectively as the “Parties.”
PATENT LICENSE AMENDMENT AGREEMENTPatent License Amendment Agreement • May 1st, 2017 • VistaGen Therapeutics, Inc. • Pharmaceutical preparations • Ontario
This Patent License Amendment Agreement (“PLAA”) is made as of December 9, 2016, by and between VistaGen Therapeutics, Inc., with principal offices located at 343 Allerton Avenue, South San Francisco, CA 94080 (“VistaGen”), and the University Health Network, an Ontario corporation, incorporated under the University Health Network Act 1997, having a business office at 101 College Street, Suite 150, Toronto, Ontario, Canada M5G 1L7 (“UHN”). VistaGen and UHN may individually be referred to as a “Party”, and collectively as the “Parties”.
